|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.42 EUR | -1.23% |
|
-2.57% | +0.84% |
| 12-20 | Guerbet Appoints François Convenant as Senior Vice President of Interventional Radiology and Member of the Executive Committee | CI |
| 12-19 | Guerbet Appoints Head of Interventional Radiology |  |
| Capitalization | 182M 211M 169M 157M 293M 19.12B 315M 1.95B 767M 9.12B 790M 774M 33.31B | P/E ratio 2025 * |
-12.2x | P/E ratio 2026 * | -106x |
|---|---|---|---|---|---|
| Enterprise value | 551M 639M 513M 477M 889M 57.96B 956M 5.9B 2.33B 27.65B 2.4B 2.35B 101B | EV / Sales 2025 * |
0.69x | EV / Sales 2026 * | 0.66x |
| Free-Float |
42.83% | Yield 2025 * |
0.42% | Yield 2026 * | 2.06% |
| 1 day | -1.23% | ||
| 1 week | -2.57% | ||
| Current month | +0.84% | ||
| 1 month | +3.59% | ||
| 3 months | -1.10% | ||
| 6 months | -33.24% | ||
| Current year | +0.84% |
| 1 week | 14.22 |  | 14.86 |
| 1 month | 13.74 | | 15.12 |
| Current year | 14.22 | | 15.12 |
| 1 year | 11.18 | | 28.2 |
| 3 years | 11.18 | | 40.25 |
| 5 years | 11.18 | | 45.65 |
| 10 years | 11.18 | | 90.64 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jérôme Estampes
CEO | Chief Executive Officer | - | 21/09/2025 |
| Chief Tech/Sci/R&D Officer | - | - | |
François Nicolas
CTO | Chief Tech/Sci/R&D Officer | 55 | 03/09/2017 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 23/05/2013 | |
Mark Fouquet
BRD | Director/Board Member | 66 | 22/05/2014 |
Didier Izabel
CHM | Chairman | 70 | 25/05/2023 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.23% | -2.57% | -45.99% | -24.90% | 211M | |
| -1.98% | -0.42% | +11.79% | -24.03% | 16.1B | |
| +4.60% | +3.96% | +54.34% | -32.80% | 3.53B | |
| -3.13% | -0.55% | +5.72% | -43.16% | 1.78B | |
| -2.89% | -1.00% | +16.59% | -16.96% | 1.7B | |
| -0.76% | -0.04% | - | - | 1.45B | |
| -0.56% | +3.08% | +72.38% | +206.31% | 1.3B | |
| -8.60% | +13.36% | +268.50% | +145.31% | 640M | |
| +2.98% | +2.13% | - | - | 292M | |
| -3.50% | -5.08% | -46.90% | +183.47% | 270M | |
| Average | -1.51% | -1.47% | +42.05% | +49.16% | 2.73B | |
| Weighted average by Cap. | -1.24% | -1.97% | +25.99% | -7.97% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 793M 920M 738M 687M 1.28B 83.49B 1.38B 8.49B 3.35B 39.82B 3.45B 3.38B 145B | 803M 932M 748M 696M 1.3B 84.57B 1.39B 8.6B 3.39B 40.34B 3.5B 3.42B 147B |
| Net income | -14.93M -17.32M -13.9M -12.94M -24.09M -1.57B -25.92M -160M -63.04M -749M -64.94M -63.6M -2.74B | -7.76M -9M -7.22M -6.72M -12.52M -817M -13.47M -83.09M -32.76M -390M -33.75M -33.06M -1.42B |
| Net Debt | 369M 428M 343M 320M 595M 38.83B 641M 3.95B 1.56B 18.52B 1.61B 1.57B 67.64B | 352M 408M 328M 305M 568M 37.04B 611M 3.77B 1.49B 17.67B 1.53B 1.5B 64.51B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 14.42 € | -1.23% | 6,062 |
| 15/01/26 | 14.60 € | +0.55% | 12,647 |
| 14/01/26 | 14.52 € | -2.16% | 15,000 |
| 13/01/26 | 14.84 € | -0.13% | 12,446 |
| 12/01/26 | 14.86 € | +0.41% | 2,502 |
Real-time Euronext Paris, January 16, 2026 at 04:55 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GBT Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition